Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 3.45B |
| Revenue (ttm) | 23.08M |
| Net Income (ttm) | -44.42M |
| Shares Out | 20.68M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $77.51 |
| Previous Close | $81.30 |
| Change ($) | -3.79 |
| Change (%) | -4.66% |
| Day's Open | 80.99 |
| Day's Range | 76.14 - 84.57 |
| Day's Volume | 79,234 |
| 52-Week Range | 26.10 - 87.83 |
Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPO...
WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule...
WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecul...
WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecul...
WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutic...
WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutic...
Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi
WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule...
Kymera reports positive data for RAK4 degrader, KT-474.
WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small mo...
Data to be presented at the 5 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeu...
WATERTOWN, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeu...
WATERTOWN, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...
WATERTOWN, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeut...
About KYMR
Kymera Therapeutics, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and... [Read more...]
| Industry Biotechnology | IPO Date Aug 21, 2020 |
| CEO Dr. Nello Mainolfi M.D., Ph.D. | Employees 64 |
| Stock Exchange NASDAQ | Ticker Symbol KYMR |
Analyst Forecasts
According to 6 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 72.00, which is a decrease of -7.11% from the latest price.